Immunopathogenesis and immunotherapy of multiple sclerosis (Q36577275)

15 August 2017

1 reference

title

Immunopathogenesis and immunotherapy of multiple sclerosis (English)

1 reference

15 August 2017

0 references

1 reference

5

Hans-Peter Hartung

1 reference

15 August 2017

4

Bernd Kieseier

1 reference

15 August 2017

Bernhard Hemmer

1

1 reference

15 August 2017

Stefan Nessler

series ordinal

2

1 reference

15 August 2017

Dun Zhou

series ordinal

3

1 reference

15 August 2017

1 April 2006

1 reference

Nature Clinical Practice Neurology

15 August 2017

1 reference

15 August 2017

2

1 reference

15 August 2017

4

1 reference

15 August 2017

201-211

1 reference

Determinants of Human B Cell Migration Across Brain Endothelial Cells

15 August 2017

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0154

Mechanisms of central nervous system viral persistence: the critical role of antibody and B cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0154

Myelin basic protein‐specific T lymphocyte lines from MS patients and healthy individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0154

Accumulation of clonally related B lymphocytes in the cerebrospinal fluid of multiple sclerosis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0154

Differential mechanisms of action of interferon-beta and glatiramer aetate in MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0154

Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0154

Interferon beta-1b in secondary progressive MS: results from a 3-year controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0154

An open label study of the effects of rituximab in neuromyelitis optica

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0154

Suppressive DNA vaccination in myelin oligodendrocyte glycoprotein peptide-induced experimental autoimmune encephalomyelitis involves a T1-biased immune response

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0154

Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0154

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0154

7 January 2021

Evidence for genetic basis of multiple sclerosis. The Canadian Collaborative Study Group.

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0154

7 January 2021

HLA class II-associated genetic susceptibility in multiple sclerosis: a critical evaluation

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0154

7 January 2021

Epidemiology of multiple sclerosis. Does this really point toward an etiology? Lectio Doctoralis

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0154

7 January 2021

Prospective study on the relationship between infections and multiple sclerosis exacerbations.

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0154

7 January 2021

Cervical lymphatics, the blood-brain barrier and the immunoreactivity of the brain: a new view

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0154

7 January 2021

Experimental autoimmune encephalomyelitis repressed by microglial paralysis.

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0154

7 January 2021

Dendritic cells permit immune invasion of the CNS in an animal model of multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0154

7 January 2021

Induction of MHC class I genes in neurons

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0154

7 January 2021

Axonal damage is T cell mediated and occurs concomitantly with demyelination in mice infected with a neurotropic coronavirus

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0154

7 January 2021

Live imaging of effector cell trafficking and autoantigen recognition within the unfolding autoimmune encephalomyelitis lesion.

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0154

7 January 2021

Unveiling the enigma of the CNS as a B-cell fostering environment

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0154

7 January 2021

The T lymphocyte in experimental allergic encephalomyelitis

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0154

7 January 2021

A pathogenic role for myelin-specific CD8(+) T cells in a model for multiple sclerosis

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0154

7 January 2021

Amino acid homology between the encephalitogenic site of myelin basic protein and virus: mechanism for autoimmunity

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0154

7 January 2021

Molecular mimicry in T cell-mediated autoimmunity: viral peptides activate human T cell clones specific for myelin basic protein

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0154

7 January 2021

Identification of high potency microbial and self ligands for a human autoreactive class II-restricted T cell clone

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0154

7 January 2021

Determinant spreading and the dynamics of the autoimmune T-cell repertoire.

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0154

7 January 2021

Epitope spreading in immune-mediated diseases: implications for immunotherapy

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0154

7 January 2021

Viral induced demyelination

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0154

7 January 2021

Borna disease virus-specific T cells protect against or cause immunopathological Borna disease

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0154

7 January 2021

Neurotrophic cross-talk between the nervous and immune systems: implications for neurological diseases

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0154

7 January 2021

Autoimmune T cells protect neurons from secondary degeneration after central nervous system axotomy

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0154

7 January 2021

Passive or active immunization with myelin basic protein impairs neurological function and exacerbates neuropathology after spinal cord injury in rats.

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0154

7 January 2021

The ups and downs of multiple sclerosis therapeutics

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0154

7 January 2021

The application of multifactorial cluster analysis in the staging of plaques in early multiple sclerosis. Identification and characterization of the primary demyelinating lesion.

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0154

7 January 2021

The adhesion molecule and cytokine profile of multiple sclerosis lesions

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0154

7 January 2021

Investigating chemokines and chemokine receptors in patients with multiple sclerosis: opportunities and challenges

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0154

7 January 2021

Axonal transection in the lesions of multiple sclerosis

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0154

7 January 2021

Acute axonal damage in multiple sclerosis is most extensive in early disease stages and decreases over time.

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0154

7 January 2021

Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0154

7 January 2021

A role for humoral mechanisms in the pathogenesis of Devic's neuromyelitis optica

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0154

7 January 2021

Relapsing and remitting multiple sclerosis: pathology of the newly forming lesion

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0154

7 January 2021

Immunology of multiple sclerosis

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0154

7 January 2021

A humanized model for multiple sclerosis using HLA-DR2 and a human T-cell receptor

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0154

7 January 2021

Cytokine phenotype of human autoreactive T cell clones specific for the immunodominant myelin basic protein peptide (83-99).

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0154

7 January 2021

Limited heterogeneity of rearranged T-cell receptor V alpha transcripts in brains of multiple sclerosis patients

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0154

7 January 2021

Clonal expansions of CD8(+) T cells dominate the T cell infiltrate in active multiple sclerosis lesions as shown by micromanipulation and single cell polymerase chain reaction

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0154

7 January 2021

Oligoclonal expansion of memory CD8+ T cells in cerebrospinal fluid from multiple sclerosis patients

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0154

7 January 2021

Multiple sclerosis: brain-infiltrating CD8+ T cells persist as clonal expansions in the cerebrospinal fluid and blood

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0154

7 January 2021

B cells and antibodies in CNS demyelinating disease

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0154

7 January 2021

Clonal expansion and somatic hypermutation of V(H) genes of B cells from cerebrospinal fluid in multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0154

7 January 2021

Maintenance of B lymphocyte-related clones in the cerebrospinal fluid of multiple sclerosis patients

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0154

7 January 2021

BAFF is produced by astrocytes and up-regulated in multiple sclerosis lesions and primary central nervous system lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0154

7 January 2021

Short-lived plasma blasts are the main B cell effector subset during the course of multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0154

7 January 2021

Recapitulation of B cell differentiation in the central nervous system of patients with multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0154

7 January 2021

The immune response at onset and during recovery from Borrelia burgdorferi meningoradiculitis

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0154

7 January 2021

IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0154

7 January 2021

A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0154

7 January 2021

Axonal and neuronal degeneration in multiple sclerosis: mechanisms and functional consequences

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0154

7 January 2021

Temporal relationship between elevation of epstein-barr virus antibody titers and initial onset of neurological symptoms in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0154

7 January 2021

Epstein-Barr virus in pediatric multiple sclerosis

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0154

7 January 2021

Antibodies against the myelin oligodendrocyte glycoprotein and the myelin basic protein in multiple sclerosis and other neurological diseases: a comparative study

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0154

7 January 2021

Identification of Epstein-Barr virus proteins as putative targets of the immune response in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0154

7 January 2021

Association of human herpes virus 6 (HHV-6) with multiple sclerosis: increased IgM response to HHV-6 early antigen and detection of serum HHV-6 DNA.

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0154

7 January 2021

Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0154

7 January 2021

Multiple sclerosis: comparison of copolymer-1- reactive T cell lines from treated and untreated subjects reveals cytokine shift from T helper 1 to T helper 2 cells

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0154

7 January 2021

Multiple sclerosis: glatiramer acetate inhibits monocyte reactivity in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0154

7 January 2021

Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0154

7 January 2021

Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0154

7 January 2021

The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0154

7 January 2021

Oral simvastatin treatment in relapsing-remitting multiple sclerosis

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0154

7 January 2021

Minocycline reduces gadolinium-enhancing magnetic resonance imaging lesions in multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0154

7 January 2021

Hematopoietic stem cell transplantation for multiple sclerosis

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0154

7 January 2021

A phase II trial of anti-CD4 antibodies in the treatment of multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0154

7 January 2021

Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0154

7 January 2021

Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon beta

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0154

7 January 2021

Induction of a non-encephalitogenic type 2 T helper-cell autoimmune responsein multiple sclerosis after administration of an altered peptide ligand ina placebo-controlled, randomized phase II trial

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0154

7 January 2021

Encephalitogenic potential of the myelin basic protein peptide (amino acids 83-99) in multiple sclerosis: results of a phase II clinical trial with an altered peptide ligand

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0154

7 January 2021

Combination of gene delivery and DNA vaccination to protect from and reverse Th1 autoimmune disease via deviation to the Th2 pathway

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0154

7 January 2021

Treatment of multiple sclerosis with T-cell receptor peptides: results of a double-blind pilot trial

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0154

7 January 2021

The ins and outs of T-lymphocyte trafficking to the CNS: anatomical sites and molecular mechanisms

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0154

7 January 2021

A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0154

7 January 2021

Natalizumab and progressive multifocal leukoencephalopathy

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0154

7 January 2021

Chemokines, sphingosine-1-phosphate, and cell migration in secondary lymphoid organs

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0154

7 January 2021

Neurosphere-derived multipotent precursors promote neuroprotection by an immunomodulatory mechanism.

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0154

7 January 2021

Identifiers

DOI

10.1038/NCPNEURO0154

1 reference

release_pomboodgpvblpcrfzcbh4vy36m

15 August 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/pomboodgpvblpcrfzcbh4vy36m

24 November 2022

mapped directly with Wikidata item

1 reference